Glycopeptide resistance in Staphylococcus haemolyticus during treatment with teicoplanin.
Blans
M
M
Troelstra
A
A
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002408:Catheters, Indwelling / Q000009:adverse effects; D004352:Drug Resistance, Microbial; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000009:adverse effects; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013210:Staphylococcus / Q000187:drug effects*; D017334:Teicoplanin / Q000494:pharmacology*; D014640:Vancomycin / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D017334:Teicoplanin; D014640:Vancomycin